Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases  Silvia Novello, MD, Carlos Camps, MD, Francesco.

Published byJuliana Kelly Modified over 5 years ago

Similar presentations

Presentation on theme: "Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases  Silvia Novello, MD, Carlos Camps, MD, Francesco."— Presentation transcript:

1 Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases  Silvia Novello, MD, Carlos Camps, MD, Francesco Grossi, MD, Julien Mazieres, MD, Lauren Abrey, MD, Jean-Marc Vernejoux, MD, Aron Thall, PhD, Shem Patyna, PhD, Tiziana Usari, BSc, Zhixiao Wang, PhD, Richard C. Chao, MD, Giorgio Scagliotti, MD  Journal of Thoracic Oncology  Volume 6, Issue 7, Pages (July 2011) DOI: /JTO.0b013e318219a973 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier estimates for progression-free survival.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318219a973) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Best percentage change from baseline in target tumor lesion size. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318219a973) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases  Silvia Novello, MD, Carlos Camps, MD, Francesco."

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in.

Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)  Chantal Decroisette,

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)  Chantal Decroisette,
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Prevalence of Brain Metastases Immediately before Prophylactic Cranial Irradiation in Limited Disease Small Cell Lung Cancer Patients with Complete Remission.

Prevalence of Brain Metastases Immediately before Prophylactic Cranial Irradiation in Limited Disease Small Cell Lung Cancer Patients with Complete Remission.
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Similar presentations

Ads by Google